89 related articles for article (PubMed ID: 25592042)
1. Gelatinases-stimuli nanoparticles encapsulating 5-fluorouridine and 5-aza-2'-deoxycytidine enhance the sensitivity of gastric cancer cells to chemical therapeutics.
Wu FL; Li RT; Yang M; Yue GF; Wang HY; Liu Q; Cui FB; Wu PY; Ding H; Yu LX; Qian XP; Liu BR
Cancer Lett; 2015 Jul; 363(1):7-16. PubMed ID: 25592042
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of decitabine-loaded gelatinases-stimuli nanoparticles in overcoming cancer drug resistance is mediated via its enhanced demethylating activity to transcription factor AP-2 epsilon.
Hong YD; Zhang J; Zhuang M; Li W; Wu PU; Li RT; Hu N; Bian BX; Song ZY; Wu FL
Oncotarget; 2017 Dec; 8(70):114495-114505. PubMed ID: 29383097
[TBL] [Abstract][Full Text] [Related]
3. Lipid-polymer nanoparticles encapsulating doxorubicin and 2'-deoxy-5-azacytidine enhance the sensitivity of cancer cells to chemical therapeutics.
Su X; Wang Z; Li L; Zheng M; Zheng C; Gong P; Zhao P; Ma Y; Tao Q; Cai L
Mol Pharm; 2013 May; 10(5):1901-9. PubMed ID: 23570548
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
5. Transcription Factor AP2ε: A Potential Predictor of Chemoresistance in Patients With Gastric Cancer.
Sun J; Du N; Li J; Zhou J; Tao G; Sun S; He J
Technol Cancer Res Treat; 2016 Apr; 15(2):285-95. PubMed ID: 25810491
[TBL] [Abstract][Full Text] [Related]
6. The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors.
Morita S; Iida S; Kato K; Takagi Y; Uetake H; Sugihara K
Oncology; 2006; 71(5-6):437-45. PubMed ID: 17690560
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
[TBL] [Abstract][Full Text] [Related]
8. Analysis of genes upregulated by the demethylating agent 5-aza-2'-deoxycytidine in gastric cancer cell lines.
Mikata R; Yokosuka O; Fukai K; Imazeki F; Arai M; Tada M; Kurihara T; Zhang K; Kanda T; Saisho H
Int J Cancer; 2006 Oct; 119(7):1616-22. PubMed ID: 16671088
[TBL] [Abstract][Full Text] [Related]
9. DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs.
Charlet J; Schnekenburger M; Brown KW; Diederich M
Biochem Pharmacol; 2012 Apr; 83(7):858-65. PubMed ID: 22280814
[TBL] [Abstract][Full Text] [Related]
10. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Reu FJ; Bae SI; Cherkassky L; Leaman DW; Lindner D; Beaulieu N; MacLeod AR; Borden EC
J Clin Oncol; 2006 Aug; 24(23):3771-9. PubMed ID: 16801630
[TBL] [Abstract][Full Text] [Related]
11. TFAP2E methylation promotes 5‑fluorouracil resistance via exosomal miR‑106a‑5p and miR‑421 in gastric cancer MGC‑803 cells.
Jingyue S; Xiao W; Juanmin Z; Wei L; Daoming L; Hong X
Mol Med Rep; 2019 Jul; 20(1):323-331. PubMed ID: 31115533
[TBL] [Abstract][Full Text] [Related]
12. TFAP2E-DKK4 and chemoresistance in colorectal cancer.
Ebert MP; Tänzer M; Balluff B; Burgermeister E; Kretzschmar AK; Hughes DJ; Tetzner R; Lofton-Day C; Rosenberg R; Reinacher-Schick AC; Schulmann K; Tannapfel A; Hofheinz R; Röcken C; Keller G; Langer R; Specht K; Porschen R; Stöhlmacher-Williams J; Schuster T; Ströbel P; Schmid RM
N Engl J Med; 2012 Jan; 366(1):44-53. PubMed ID: 22216841
[TBL] [Abstract][Full Text] [Related]
13. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles.
Liu Q; Li RT; Qian HQ; Wei J; Xie L; Shen J; Yang M; Qian XP; Yu LX; Jiang XQ; Liu BR
Biomaterials; 2013 Sep; 34(29):7191-203. PubMed ID: 23806972
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Shin SH; Park SY; Kang GH
Am J Pathol; 2013 Apr; 182(4):1275-85. PubMed ID: 23402999
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
Moro H; Hattori N; Nakamura Y; Kimura K; Imai T; Maeda M; Yashiro M; Ushijima T
Gastric Cancer; 2020 Jan; 23(1):105-115. PubMed ID: 31555951
[TBL] [Abstract][Full Text] [Related]
17. The DNA hypomethylating agent, 5-aza-2'-deoxycytidine, enhances tumor cell invasion through a transcription-dependent modulation of MMP-1 expression in human fibrosarcoma cells.
Poplineau M; Schnekenburger M; Dufer J; Kosciarz A; Brassart-Pasco S; Antonicelli F; Diederich M; Trussardi-Régnier A
Mol Carcinog; 2015 Jan; 54(1):24-34. PubMed ID: 24038389
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic reversal of acquired resistance to 5-fluorouracil treatment.
Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
Mol Cancer Ther; 2009 May; 8(5):1045-54. PubMed ID: 19383845
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine and the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
Chik F; Machnes Z; Szyf M
Carcinogenesis; 2014 Jan; 35(1):138-44. PubMed ID: 23985780
[TBL] [Abstract][Full Text] [Related]
20. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
